John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc., filed a Form 4 on September 16, 2026, reporting the exercise of stock options and acquisition of common stock on September 15, 2026.
Key Highlights
- Option exercise: Quisel exercised a stock option (transaction code M) covering 36,000 shares of Common Stock on September 15, 2026.
- Exercise price: The conversion or exercise price of the stock option was $1.01 per share.
- Price of derivative security: The filing reports the price of the derivative security as $0.
- Resulting common stock ownership: Following the transaction, Quisel directly beneficially owned 262,064 shares of Common Stock.
- Remaining options: After the exercise, Quisel directly held 150,120 stock options (right to buy), with an expiration date of March 10, 2030.
- Vesting status: According to the filing, "The shares underlying this option are fully vested and exercisable as of the date hereof."
Disc Medicine CEO Reports Option Exercise and Updated Beneficial Ownership
According to the Form 4 filed with the SEC on September 16, 2026, John D. Quisel, who serves as both Chief Executive Officer and Director of Disc Medicine, Inc. (NASDAQ:IRON), reported a single transaction dated September 15, 2026. The transaction involved the exercise of a stock option with an exercise price of $1.01, resulting in the acquisition of 36,000 shares of Common Stock, coded as an "M" transaction in Table I of the filing.
In Table II, covering derivative securities, the filing records the same September 15, 2026 transaction: 36,000 stock options (right to buy) were disposed of via the exercise, at an exercise price of $1.01, with an expiration date of March 10, 2030. The price of the derivative security is listed as $0. The filing notes in its explanation of responses that "The shares underlying this option are fully vested and exercisable as of the date hereof." Following the reported transaction, Quisel directly holds 150,120 remaining stock options of the same series.
After the exercise, Quisel's direct beneficial ownership of Disc Medicine Common Stock stands at 262,064 shares, as reported in Table I of the filing. The Form 4 was signed by Rahul Khara as Attorney-in-Fact on September 16, 2026, and indicates this was a filing by one reporting person.
What Was Disclosed
The filing discloses that CEO John D. Quisel exercised 36,000 fully vested stock options in Disc Medicine, Inc. at $1.01 per share on September 15, 2026, bringing his direct common stock ownership to 262,064 shares and leaving 150,120 options remaining.



Please wait processing your request...